Comparative Pharmacology
Head-to-head clinical analysis: ROWASA versus SFROWASA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ROWASA versus SFROWASA.
ROWASA vs SFROWASA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
5-aminosalicylic acid (5-ASA) inhibits prostaglandin and leukotriene synthesis, reduces neutrophil chemotaxis, and scavenges reactive oxygen species, thereby exerting anti-inflammatory effects on the colonic mucosa.
SFROWASA is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
Rectal suspension enema: 4 g (60 mL) once daily at bedtime, retained for at least 8 hours. Rectal suppository: 500 mg twice daily (one in the morning and one at bedtime).
5-aminosalicylic acid (mesalamine) 1 g orally 4 times daily for acute treatment; maintenance 500 mg orally 3 times daily.
None Documented
None Documented
Terminal elimination half-life of mesalamine (5-ASA) is approximately 0.5-2 hours; N-acetyl-5-ASA half-life is 5-10 hours. Rectal administration prolongs local retention without altering systemic half-life.
Terminal elimination half-life: 12-14 hours in healthy adults; prolonged in hepatic impairment (up to 24 hours) or severe renal disease (up to 20 hours).
Renal: approximately 78% (primarily N-acetyl-5-ASA and unchanged 5-ASA). Fecal: approximately 20% (unabsorbed drug). Biliary: negligible (<1%).
Renal: 80% as unchanged drug; biliary/fecal: <15% as metabolites; minor hepatic metabolism via CYP3A4.
Category C
Category C
Aminosalicylate
Aminosalicylate